Darunavir: In the treatment of HIV-1 infection

Drugs

Volumn 67, Issue 18, 2007, Pages 2791-2801

  Fenton, Caroline ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Darunavir, general; HIV infections; Research and development

Indexed keywords

ATAZANAVIR; ATORVASTATIN; DARUNAVIR; DIGOXIN; EFAVIRENZ; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; OMEPRAZOLE; PRAVASTATIN; PREZISTA; PROTEINASE INHIBITOR; RANITIDINE; RITONAVIR; SILDENAFIL; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DATA ANALYSIS; DIARRHEA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INJECTION SITE REACTION; INSOMNIA; NAUSEA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VIRUS ISOLATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 36849030792     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767180-00010     Document Type: Review

References (45)

1. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://www.aidsinfo.nih.gov/contentfiles/AdultsandAdolescentsGL.pdf [Accessed 2007 Aug 25]
2. Gazzard on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; (7): 487-503
3. The EACS Executive Committee. European Guidelines for the clinical management and treatment of HIV infected adults [online]. Available from URL: http://www.eacs.wa [Accessed 2007 Aug 25]
4. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a treatment-broad range of clinical isolates. Antimicrob Agents Chemother 2005 Jun; 49 (6): 2314-21
5. Volberding PA. Meeting challenges: overcoming limitations. Advances of the protease inhibitor class: proceedings of an Expert Roundtable. J Acquir Immune Defic Syndr 2004; 35 Suppl. 1: S1-2
6. Tibotec. PREZISTATM (darunavir) summary of product characteristics. [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ prezista/H-707-PI-en.pdf [Accessed 2007 Dec 1]
7. Tibotec Therapeutics. PREZISTATM US prescribing information [online]. Available from URL: http://www.prezista.com/docs/us_package_insert.pdf [Accessed 2007 Dec 1]
8. Boffito M, Moyle GJ. Pharmacokinetic considerations for combining 2 protease inhibitors. AIDS Read 2004; 14 (3): 110-6
9. King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004 Nov; 78 (21): 12012-21
10. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane- containing nonpeptide protease inhibitor (PI) IUC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003 Oct; 47 (10): 3123-9
11. Tie Y, Boross PI, Wang YF, et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 2004 Apr 23; 338 (2): 341-52
12. Turner D, Schapiro JM, Brenner BG, et al. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antiviral Ther 2004; 9 (3): 301-14
13. Molla A, Kohlbrenner W. Evolving therapeutic paradigms for HIV and HCV. Curr Opin Biotechnol 2003; 14 (6): 634-40
14. De Meyer S, Hill A, De Baere I, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy [oral presentation]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-9; Denver (CO)
15. Sekar V, De Meyer S, Vangeneugden T, et al. Pharmacokinetic/ pharmacodynamic(PK/PD) analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients [poster]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-9; Denver (CO)
16. De Meyer S, Hill A, De Baere, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: preliminary analysis of data from PI-experienced patients from POWER 1 and POWER 2 [abstract and poster]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-9; Denver (CO)
17. Pozniak A. Efficacy of TMC114/r in treatment-experienced HIV patients: factors influencing outcome in the pooled 24 week analysis of POWER 1, 2 and 3 [abstract no. P3]. 12th Annual Conference of the British HIV Association; 2006 Mar 29-Apr 1; Brighton
18. Picchio G, Vangeneugden T, Van Baelen B, et al. Prior utilization or resistance to amprenavir at screening has minimal effect on the 48-week response to darunavir/r in the POWER 1, 2, and 3 studies [abstract no. 609]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
19. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) With low-dose ritonavir in treatment-experienced Patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007 Jul 5; 46 (1): 24-31
20. Arasteh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive anti-retroviral regimen: a 14-day proof-of-principle trial. AIDS 2005 Jun 10; 19 (9): 943-7
21. Hoetelmans R, Marien K, De Pauw M, et al. Pharmacokinetic interaction between TMC114/ritonavir (RTV) and tenofovir in healthy volunteers [abstract no. TuPeB4634]. eJournal of the International AIDS Society 2004 Jul 11; 6 (3)
22. Hoetelmans RMW, Lasure A, Koester A, et al. The effect of TMC114, a potent next-generation HIV protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics [abstract no. H-865]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
23. Sekar V, Hoetelmans R, De Marez T, et al. Pharmacokinetics of TMC114: effect of omeprazole and ranitidine [abstract no. WePe3.3C13]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 Jul 24-27; Rio de Janiero
24. Hoetelmans R, Lefebvre E, van der Sandt I, et al. Pharmacokinetics and effect of food on TMC114, a potent next generation protease inhibitor, boosted with low dose ritonavir [abstract plus poster]. 5th International Workshop on Clinical Pharmacology of HIV therapy; 2004 Apr 1-3; Rome
25. Hoetelmans R, Van der Sandt I, De Pauw M, et al. TMC 114, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers [abstract no. 549]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston (MA)
26. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 2007 Apr; 47 (4): 479-84
27. Boffito M, Winston A, Fletcher C, et al. Pharmacokinetics (PK) and antiretroviral (ARV) response to TMC 114/r and TMC 125 combination in patients with high level viral resistance [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 2006 Feb 5-9; Denver (CO)
28. Arasteh K, Clumeck N, Pozniak A, et al. Antiretroviral activity, safety and pharmacokinetics of TMC114, a next-generation HIV-1 protease inhibitor (PI), in multiple PI-experienced patients [abstract]. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment LBA; 2003 Jul 13-16; Paris
29. Peeters M, Van Baelen B, De Meyer S, et al. TMC114/RTV activity in multiple PI-experienced patients: correlation of baseline genotype, phenotype, pharmacokinetics, and IQ with antiviral activity at day 14 [abstract no. 533]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA)
30. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Pharmacocet kinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with impaired hepatic function [abstract no. TUPDB05]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-25; Sydney
31. Hoetelmans R, van der Sandt I, De Pauw M, et al. TMC114, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers [abstract no. 39]. 4th International Workshop on Clinical Pharmacology of HIV Therapy; 2003 Mar 27-29; Cannes
32. Sekar V, De Marez T, Spinosa-Guzman S, et al. Pharmacokinetic interaction between TMC114/ritonavir and atazanavir in healthy volunteers [abstract no. PE4.3/4 plus poster]. 10th European AIDS conference; 2005 Nov 17-20; Dublin
33. Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between TMC114/r and omeprazole or ranitidine in HIV-negative healthy volunteers. Antimicrob Agents Chemother 2007 Mar; 51 (3): 958-61
34. Sekar VJ, Lefebvre E, Boogaerts G, et al. Pharmacokinetic interaction between the protease inhibitors TMC114 and lopinavir/ritonavir [abstract]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA). 2006
35. Sekar VJ, Lefebvre E, De Marez T, et al. Pharmacokinetic interaction between TMC114, a new protease inhibitor and sildenafil [abstract]. 46th Interscience Conference on Antikinetics microbial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
36. Pecini R, Vangeneugden T, Sekar V. Darunavir in combination with other medications: pharmacokinetic interactions [poster S3-5]. American Conference for the Treatment of HIV (AC-THIV); 2007 May 31-Jun 3; Dallas (TX)
37. Sekar VJ, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetic interaction trial between darunavir in combination with low-dose ritonavir and didanosine [abstract no. M15682]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-25; Sydney
38. Sekar VJ, De Pauw M, Marien K, et al. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir Ther 2007; 12 (4): 509-14
39. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007 Feb 19; 21 (4): 395-402
40. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007 Mar 30; 21 (6): F11-8
41. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007 Apr 7; 369 (9568): 1169-78
42. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007 Jul 7; 370 (9581): 49-58
43. Valdez-Madruga J, Berger DE, McMurchie M, et al. Comparison of 48-week efficacy and safety of darunavir/ritonavir (DRV/r) with lopinavir/ritonavir (LPV/r) in LPV/r-naive, treatment-experienced patients: a randomised, controlled phase III trial (TITAN) [abstract no. TUAB101; plus oral presentation]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-25; Sydney
44. Tibotec Pharmaceuticals Limited. TMC114-C211: trial of an investigational protease inhibitor TMC114 with ritonavir (TMC114/r) in HIV-1 infected patients who have never been treated with antiretroviral medications [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00258557 [Accessed 2006 Feb 20]
45. Rachlis A, Clotet B, Baxter J, et al. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials 2007 Jul 31; 8 (4): 213-20